Tech stocks dominated the news after the closing bell on Thursday, but one of the biggest movers was health name
, which surged nearly 13%.
The California-based company disclosed after the market's close that its Kuvan drug, which just received regulatory approval to treat a genetic disorder called phenylketonuria, should generate 2008 revenue of between $35 million and $70 million. That's based on a planned list price of 29 cents per milligram, which the company expects will translate into an average annual therapy cost of $57,000 per patient.
BioMarin shares, which got an upward jolt in Thursday's regular session following the midday approval news, were climbing $3.74 to $33.50 in recent after-hours trading.
As for tech winners,
flew 18.2% higher after announcing it had struck a ten-year polysilicon supply deal with France-based silicon maker Silicium de Provence, or Silpro. Shipments will kick off in mid-2010. Terms weren't disclosed. Evergreen says this brings it up to 100% of the silicon it will need for fulfilling its goal to sell more than 1 gigawatt worth of solar panels from 2008 through 2012. Shares of the Marlboro, Mass., company were up $2.75 to $17.86.
was jumping as well, after fiscal third-quarter revenue shot up 39.7% from last year to a better-than-expected $409.7 million. Its loss also widened substantially to 64 cents a share from a penny a share last year, though 55 cents of that was due to ballooning interest from an increase in debt, as well as a change in its tax-accounting method. Analysts were looking for a per-share loss of 15 cents. Shares of the San Diego-based company added $3.37, or 9.9%, to $37.51, after the close.
And Denver phone giant
bounced 6.3% to $7.40 after
declaring its first dividend since 2001. The 8-cent per-share distribution will pay out on Feb. 21 to shareholders of record on Feb. 1.
On the losing side,
slid more than 11% after the Waltham, Mass., security software maker projected fiscal 2008 sales of between $920 million and $945 million. Analysts are looking for $954.8 million, stripping out $26 million in expected revenue from its discontinued Swiss consulting business, which was sold off during the fiscal fourth quarter.
For that quarter, Novell reported an adjusted profit of 6 cents a share, which tops targets by 2 cents, and the company beat on revenue, as well. On a GAAP basis, it swung to a quarterly loss vs. last year. Shares were off 80 cents to $6.30 in recent late trading.
Out of the tech sector, sportswear retailer
likewise reported swinging to a GAAP-based loss in the fiscal fourth quarter. On a pro forma basis, the Huntington Beach, Calif., company said continuing-operations income came to 51 cents a share, a penny shy of Street views. Revenue, at $779.2 million, was also slightly under. And it expects a fiscal 2008 top line of just $2.7 billion against current expectations for $2.74 billion.
Shares slid 72 cents, or 7.1%, to $9.45, in recent after-hours action.
As originally published, this story contained an error. Please see
Corrections and Clarifications.